Drug
GV1001 Placebo
GV1001 Placebo is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_2
3
60%
Ph phase_3
2
40%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 32 (40.0%)
Trials by Status
not_yet_recruiting120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
not_yet_recruitingphase_3
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
NCT05303701
completedphase_2
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
NCT05819658
completedphase_2
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
NCT06235775
completedphase_2
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210
completedphase_3
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
NCT04032067
Clinical Trials (5)
Showing 5 of 5 trials
NCT05303701Phase 3
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
NCT05819658Phase 2
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
NCT06235775Phase 2
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
NCT05189210Phase 2
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT04032067Phase 3
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5